Express Scripts

Express Scripts
Name	Express Scripts
Type	Subsidiary
Industry	Pharmaceutical services
Founded	1986
Headquarters	St. Louis, Missouri, United States
Key people	Tim Wentworth
Parent	Cigna

Express Scripts

Express Scripts is a large pharmacy benefit manager and prescription fulfillment organization based in the United States. The company administered prescription drug plans for employers, health plans, unions, and government programs, processing claims, negotiating with pharmaceutical manufacturers, and operating mail-order and specialty pharmacies. Its operations intersected with major pharmaceutical manufacturers, health insurers, and regulatory agencies, making it a central player in discussions involving United States Department of Health and Human Services, Food and Drug Administration, Centers for Medicare & Medicaid Services, Cigna, and major drugmakers such as Pfizer, Merck & Co., Johnson & Johnson, and Eli Lilly and Company.

History

Founded in 1986 by a group of distributors and pharmacists, the company grew rapidly through organic expansion and a series of strategic deals. Early investors and backers included regional pharmacy chains and private equity firms associated with St. Louis, Missouri Botanical Garden, and local business networks. Over time it competed with other pharmacy benefit managers like Caremark, Prime Therapeutics, OptumRx, and national pharmacy chains including Walgreens Boots Alliance and CVS Health. The firm attracted board members and executives with prior ties to corporations such as IBM, Procter & Gamble, McKesson Corporation, and finance groups linked to Goldman Sachs and JPMorgan Chase. Its trajectory reflected consolidation trends that involved participants such as Aetna, Anthem, Inc., and Blue Cross Blue Shield Association.

Services and Operations

The organization provided mail-order pharmacy services, specialty pharmacy management, formulary design, medication adherence programs, and claims adjudication. Clients included large employers, unions, and public programs influenced by policies from the Department of Veterans Affairs, Social Security Administration, and municipal benefit plans in cities like New York City and Chicago. It negotiated drug prices and rebates with manufacturers including Novartis, Roche, GlaxoSmithKline, and distributors like Cardinal Health and AmerisourceBergen. The company operated pharmacy networks including community pharmacies affiliated with chains such as Rite Aid and independent pharmacies that participated in programs connected to organizations like National Community Pharmacists Association and trade groups such as Pharmaceutical Research and Manufacturers of America.

Business Model and Financials

Revenue streams derived from administrative fees, spread pricing, mail-order fulfillment, specialty drug dispensing, and manufacturer rebates. Financial reporting and investor relations engaged entities such as Securities and Exchange Commission, investment banks like Morgan Stanley, and rating agencies including Moody's Investors Service and Standard & Poor's. The company’s profit margins, cost-control strategies, and rebate negotiations were examined by analysts at firms including Goldman Sachs, Bank of America Merrill Lynch, and UBS. Major expenditure categories included specialty drug acquisition, technology investments tied to vendors like Oracle Corporation and McKesson Corporation, and contracting costs with benefit consultants such as Mercer and Aon.

Mergers, Acquisitions, and Partnerships

The company pursued acquisitions of regional pharmacy services and specialty providers, engaging merger advisors from firms such as Lazard and Evercore. It entered strategic alliances and long-term contracts with insurers and health systems, including discussions involving Humana, Kaiser Permanente, and Mount Sinai Health System. Major corporate transactions attracted scrutiny from shareholders and institutional investors like Vanguard Group, BlackRock, and Berkshire Hathaway observers. The firm’s consolidation activities paralleled industry moves by CVS Health acquiring Aetna and Cigna completing its own transactions, reshaping competitive dynamics against peers such as UnitedHealth Group and its Optum division.

Regulatory and Legal Issues

Regulators and legislators from the United States Congress and agencies such as the Department of Justice examined pharmacy benefit manager practices, including rebate structures, reimbursement methodology, and network steering. Litigation involved state attorneys general from jurisdictions like California, New York (state), and Texas (state), as well as class actions brought by employers, unions, and independent pharmacies represented by law firms with ties to courts such as the United States District Court for the Eastern District of Missouri and the United States Court of Appeals for the Eighth Circuit. Policy debates referenced statutes and programs including Medicare Part D, Medicaid (United States), and federal procurement rules overseen by the Office of Management and Budget.

Corporate Governance and Leadership

Leadership teams included executives with backgrounds at multinational corporations and healthcare organizations, with board members connected to institutions such as Harvard University, Washington University in St. Louis, Northwestern University, and professional networks tied to American Pharmacists Association. Institutional shareholders and activist investors such as Elliott Management Corporation and other asset managers influenced governance discussions about executive compensation, strategic direction, and potential divestitures. Corporate governance practices were evaluated against standards promoted by groups like the Securities and Exchange Commission and investor stewardship codes endorsed by organizations including Council of Institutional Investors.

Category:Pharmacy benefit managers